Galux is pushing AI protein design, aiming for bigger global pharma deals by BIO USA 2026. This indicates a clear industry focus on advanced AI applications for drug discovery and development.
Why It Matters
For European small biotech and CROs, this highlights a specific area where AI is already delivering value. My experience with Grupo Moja Farmacja showed me how critical early-stage R&D innovation is for smaller players. If you are not exploring AI for protein design or similar drug discovery challenges, you are falling behind your global competitors. This is not about speculation; it is about actual deals being pursued in a highly competitive market.
What To Do About It
Review your current R&D pipeline. Identify one specific protein design or drug discovery bottleneck where AI could offer a tangible speed or cost advantage. Then, check if your Microsoft 365 Copilot subscription offers any relevant plugin or capability for initial data analysis before considering external tools.
Sources
Related Signals
Nature published a cautionary tale about RAG in clinical practice.
4 Jul 2026
Mankind Pharma partnered with Denovo Sciences for AI-led drug discovery.
2 Jul 2026
Logicboots introduced Coeur.AI at VivaTech Paris 2026. This launch is part of Logicboots' strategy to expand its global footprint through startup accelerators.
28 Jun 2026